At Janssen, we are dedicated to doing our part to help children and young people living with HIV thrive and reach adulthood. Our company has a long history of working to improve the lives and well-being of children living with HIV. Our efforts include many programs to prevent infection, develop new medicines, and provide care and treatment for children and adolescents with HIV.
Addressing pediatric HIV remains a significant challenge across sub-Saharan Africa and other resource-limited settings. Of more than 3 million children living with HIV, only 23 percent receive treatment, and a small but growing number of those receiving treatment in resource-limited settings are failing first-line therapy. Our collaborative initiative ‒ New Horizons Advancing Pediatric HIV Care ‒ is designed to advance care for these children and adolescents. This initiative seeks to address this unmet need and improve access to our approved HIV medicines, including child-friendly formulations, for vulnerable patients living in least-developed countries.
We’re working with a number of organizations, including the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), Supply Chain Management Systems (SCMS), the International AIDS Society (IAS) and MAP International, to fully maximize the program’s impact. In 2014, Ministries of Health in sub-Saharan Africa were invited to submit an Expression of Interest to participate in the initiative. An independent Review Committee of international experts in pediatric HIV has since carefully assessed all applications. To date, four countries have been determined to be eligible for participation – Kenya, South Africa, Swaziland and Zambia. We are working with clinicians and Ministries of Health to equip local health systems with the resources, data and tools necessary for the long-term delivery of medicines and care for these children. To meet the needs of treatment-experienced children globally, we have expanded the scope of the initiative to countries beyond sub-Saharan Africa.
We hope that New Horizons catalyzes a broader collaborative effort to build awareness, accelerate action, and advance learning around the needs of children and adolescents experiencing HIV treatment failure globally.